2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efficient production of bispecific antibodies—optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bispecific antibodies (bsAbs) are often composed of more than two component chains, such as Fabs-in-tandem immunoglobin (FIT-Ig) comprising three different component chains, which bring challenges for generating a high proportion of the correctly assembled bsAbs in a stable cell line. During the CHO-K1 stable cell line construction of a FIT-Ig, we investigated the FIT-Ig component chain ratio in transfection, where two sets of expression vectors were designed. Both designs utilized two vectors for co-transfection. Multiple transfections with plasmid ratio adjustment were applied, and the resultant minipools were evaluated for expression titer and quality of produced FIT-Ig. The results suggested that abundant outer Fab short chains (twofold chain genes versus other chains) can promote complete FIT-Ig assembly and therefore reduce the fragmental impurities of FIT-Ig. This adjustment of the component chain ratios at the beginning is beneficial to FIT-Ig stable cell line generation and brings favorable clones to process development.

          Abstract

          Statement of Significance: Bispecific antibodies are often composed of more than two component chains, which bring challenges to production, particularly in a stable cell line. These challenges can be addressed by rational vector design and transfection strategy as well as rational screening funnel for high-level stable clones.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Bispecific antibodies: a mechanistic review of the pipeline

          The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from relatively small proteins, merely consisting of two linked antigen-binding fragments, to large immunoglobulin G (IgG)-like molecules with additional domains attached. An attractive bsAb feature is their potential for novel functionalities - that is, activities that do not exist in mixtures of the parental or reference antibodies. In these so-called obligate bsAbs, the physical linkage of the two binding specificities creates a dependency that can be temporal, with binding events occurring sequentially, or spatial, with binding events occurring simultaneously, such as in linking an effector to a target cell. To date, more than 20 different commercialized technology platforms are available for bsAb creation and development, 2 bsAbs are marketed and over 85 are in clinical development. Here, we review the current bsAb landscape from a mechanistic perspective, including a comprehensive overview of the pipeline.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The making of bispecific antibodies

            ABSTRACT During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The ‘zoo’ of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG structure, and large complex molecules composed of different antigen-binding moieties often combined with dimerization modules. The application of sophisticated molecular design and genetic engineering has solved many of the technical problems associated with the formation of bispecific antibodies such as stability, solubility and other parameters that confer drug properties. These parameters may be summarized under the term ‘developability’. In addition, different ‘target product profiles’, i.e., desired features of the bispecific antibody to be generated, mandates the need for access to a diverse panel of formats. These may vary in size, arrangement, valencies, flexibility and geometry of their binding modules, as well as in their distribution and pharmacokinetic properties. There is not ‘one best format’ for generating bispecific antibodies, and no single format is suitable for all, or even most of, the desired applications. Instead, the bispecific formats collectively serve as a valuable source of diversity that can be applied to the development of therapeutics for various indications. Here, a comprehensive overview of the different bispecific antibody formats is provided.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.

              We describe a generic approach to assemble correctly two heavy and two light chains, derived from two existing antibodies, to form human bivalent bispecific IgG antibodies without use of artificial linkers. Based on the knobs-into-holes technology that enables heterodimerization of the heavy chains, correct association of the light chains and their cognate heavy chains is achieved by exchange of heavy-chain and light-chain domains within the antigen binding fragment (Fab) of one half of the bispecific antibody. This "crossover" retains the antigen-binding affinity but makes the two arms so different that light-chain mispairing can no longer occur. Applying the three possible "CrossMab" formats, we generated bispecific antibodies against angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) and show that they can be produced by standard techniques, exhibit stabilities comparable to natural antibodies, and bind both targets simultaneously with unaltered affinity. Because of its superior side-product profile, the CrossMab(CH1-CL) was selected for in vivo profiling and showed potent antiangiogenic and antitumoral activity.
                Bookmark

                Author and article information

                Contributors
                Journal
                Antib Ther
                Antib Ther
                anther
                Antibody Therapeutics
                Oxford University Press
                2516-4236
                July 2023
                27 June 2023
                27 June 2023
                : 6
                : 3
                : 170-179
                Affiliations
                Shanghai EpimAb Biotherapeutics Co., LTD , 6F, Building 2, 4560 Jinke Road, Shanghai 201203, China
                Shanghai EpimAb Biotherapeutics Co., LTD , 6F, Building 2, 4560 Jinke Road, Shanghai 201203, China
                Author notes
                To whom correspondence should be addressed. Chengbin Wu, Shanghai EpimAb Biotherapeutics Co., LTD, 6F, Building 2, 4560 Jinke Road, 201203 Shanghai, China. Email: ( cw@ 123456epimab.com )
                Article
                tbad013
                10.1093/abt/tbad013
                10365153
                6e11cef8-227b-46f4-8562-41df00f34989
                © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 20 September 2022
                : 4 May 2023
                : 24 May 2023
                : 28 June 2023
                Page count
                Pages: 10
                Funding
                Funded by: Shanghai EpimAb Biotherapeutics Co., LTD;
                Categories
                Bispecific Antibody CMC
                AcademicSubjects/SCI01030
                AcademicSubjects/SCI00100

                bispecific antibody,fit-ig,stable cell line,vector,transfection,fragmental molecule,process development

                Comments

                Comment on this article